小叶臭黄皮咔唑生物碱化学成分及其抗肿瘤活性研究

目的研究小叶臭黄皮Clausena excavate根的化学成分及抗肿瘤活性。方法采用硅胶、RP-18和HPLC等色谱技术分离纯化,根据理化常数和波谱数据鉴定化合物的结构,采用SRB法测定化合物1、2、7、8、10的细胞毒活性。结果从小叶臭黄皮根的甲醇提取物中分离得到13个咔唑生物碱,分别鉴定为2,3-二甲氧基-3-羧基咔唑生物碱(1)、1-羟基-3-甲酸甲酯咔唑生物碱(2)、7-羟基-3-醛基咔唑生物碱(3)、2,7-二甲氧基-3-甲酸甲酯咔唑生物碱(4)、7-羟基-3-甲酸甲酯咔唑生物碱(5)、2-羟基-3-醛基咔唑生物碱(6)、1-羟基-3-醛基咔唑生物碱(7)、2,3-二羟基-3-醛基咔唑生物碱(8)、3-醛基咔唑生物碱(9)、6-甲氧基-3-醛基咔唑生物碱(10)、7-甲氧基-3-甲酸甲酯咔唑生物碱(11)、2-甲氧基-3-羧基咔唑生物碱(12)、1,6-二羟基-3-醛基咔唑生物碱(13)。结论化合物9、10、12为首次从该植物中分离得到。化合物1、2、7、8、10对3种人体肿瘤细胞(A549、He La和BGC-823)均有不同程度的杀伤作用,IC50为8.53~19.87μg/m L。     

瘦素对胰岛β细胞胰岛素分泌及葡萄糖信号传递的影响

瘦素是近年发现的一种与肥胖症有关的激素。它通过与下丘脑特异受体结合 ,发挥维持机体正常体重的功能。同时瘦素对胰岛素分泌及胰岛素的外周作用亦存在影响 ,但结果不一 ,对其作用机制尚少有报道。我们研究瘦素对胰岛素分泌的急性与慢性影响 ,并通过观察细胞内游离钙、葡萄糖激酶 (ＧＫ)ｍＲＮＡ表达的变化 ,初步探讨瘦素影响胰岛素分泌的机制。一、研究方法1.胰岛 β细胞培养 :β ＴＣ3 细胞 (由美国爱因斯坦大学Ｅｆｒａｔ教授惠赠 )以含 15 %马血清、2 5 %胎牛血清 (ＰＢＳ)、10 0Ｕ/ｍｌ青霉素、0 1ｍｇ/ｍｌ链霉素的ＤＭＥＭ培养液 …     

肾动脉狭窄支架置入术疗效随访观察

目的 评价肾动脉狭窄病人支架置入术的中长期疗效.方法 选取广东省心血管病研究所2000年3月～2003年12月行肾动脉支架置入术208例,分别在术前、术后住院期间、术后随访至少6个月的病人血压、服用抗高血压药和检测血清肌酐水平,记录手术并发症及随访病人的临床不良事件.结果 208例共254条肾动脉成功放置了支架,主要临床不良事件发生率约为1.9%.随访期血清肌酐从术前(189±6) μmol/L,下降至(146±5) μmol/L(P=0.007),血压从术前(163±12)/(101±9)mm Hg(1 mm Hg=0.133 kPa)下降至(136±11)/(76±7) mm Hg(P=0.02).结论 肾动脉支架置入术是一种安全、有效治疗肾动脉狭窄的方法.     

网络化环境科技期刊发展策略

阐述网络化环境下科技期刊以"内容为王"的竞争优势,网络化给科技期刊的出版发行拓展了新的渠道;网络化环境科技期刊发展策略需要在品牌上下工夫、创造新的市场份额、增强出版行为的市场化、拓展传统媒体的新空间、整合出版资源;网络化环境科技期刊出版模式可以从集团式、合作式、开放存取式等方面去丰富;建立网络环境下快速出版的机制及学术团体指导机制,提出传统出版应该以技术发展商为重要的辅助手段扩大影响和宣传,进一步开发自身价值。只有传统出版主导数字出版产业,才能保证我国的数字出版产业健康、有序的发展。     

高钾摄入对家兔血管内皮损伤后的抗增生作用

目的：观察高钾摄入对血管内皮损伤后的抗增生功能，探讨其对再狭窄的预防作用。方法：高脂饲养家兔分为钾剂治疗组（3％KCl100ml/d）和对照组，经髂动脉球囊扩张术建立血管内皮损伤模型，另设正常饮食和非髂动脉球囊扩张术的空白对照组，观察术后脂质过氧状况、血小板聚集功能、血管条3H-TdR掺入量和血管病理形态学改变。结果：（1）对照组MDA和PRMA均较空白组和治疗组显著升高（术后7天P＜0．05，术后30天P＜0.01），而空白组与治疗组之间无明显差异（P＞0．05）；对照组和治疗组SOD在术后30天均较空白组下降（P＜0．05）。（2）对照组3H－TdR掺入量较空白组明显升高（术后7天P＜0．01，术后30天P＜0．05），治疗组3H．TdR掺入量则较对照组明显下降（术后7天P＜0．01，术后30天P＜0．05）。（3）对照组管腔面积较治疗组明显减小（术后30天P＜0．01），而新生内膜面积、新生内膜面积／中膜面积治疗组显著低于对照组（术后7天P＜0.05），术后30天（P＜0．01）。结论：钾具有抗内膜增殖、抗氧化、抗血小板聚集等作用，可有效地抑制血管内皮损伤后再狭窄的发生。     

Impact of prolonged dual antiplatelet therapy on patients after drug-eluting stents implantation

Background Impact of dual antiplatelet therapy beyond 12 months on patients implanted with DES remains unsolved.Methods From January 2010 to June 2011,1873 patients who have been taking DAPT and free from death,myocardial infarction,stroke,repeat coronary revascularization,stent thrombosis,and major or minor bleeding according to TIMI criteria for 12 months after implantation of DES were randomly assigned to continuous (prolonged DAPT group) or discontinuous (standard DAPT group) clopidogrel (75 mg/day).The primary outcome was major adverse cardiovascular events (MACEs) which compose of death,nonfatal myocardial infarction (MI),nonfatal stroke,target vessel revascularization (TVR) or stent thrombosis (ST) at 180 days.Results There was no significant difference in the incidence of 180-day MACEs between prolonged DAPT group and standard DAPT group (8.98 % versus 10.13 %,respectively,P=0.400).The frequency of major bleeding was 0.64 % in prolonged DAPT arm and 0.43% in standard DAPT arm (P=0.523),that of minor bleeding was 3.32 % versus 2.87 % (P=0.585),respectively.Conclusions Prolonged DAPT beyond 12 months neither improve prognosis nor increase risk of bleeding in patients implanted with DES.     

Comparison of benefit and safety between different loading dose of clopidogrel on elderly patients undergoing primary percutaneous cronary intervention for ST-segment elevation myocardial infarction

Background Despite the proven benefit of 600-mg loading dose of clopidogrel in patients with acute ST-segment elevation myocardial infarction (STEMI) who undergo primary percutaneous cronary intervention (PCI), there is still concern about its benefit and safety on elderly population. Methods Data of 172 consecutive elderly patients (≥75 years) with STEMI who underwent primary PCI at Guangdong Provincial Cardiovascular Institute from January 2008 to December 2011 were retrospectively collected. Patients were divided into 600-mg loading clopidogrel group and 300-mg clopidogrel group accoring to the loading dose of clopidogrel before primary percunaeous coronary intervention(PCI). Enzymatic myocardial infarction size estimated by peak creatine kinase-myocardial band (CK-MB) and patency of the infarct-related artery (IRA) were compared. Thirty-day major adverse cardiac events (MACEs), which consist of death, nonfatal myocardial infarction (MI), nonfatal stroke, target vessel revascularization (TVR) or stent thrombosis (ST) were compared to assess the efficacy of different loading dose. Bleeding information was compared as well to assess the safety of different pretreatment stragety before primary PCI. Results 96 patients were adminstered with 600-mg loading clopidogrel before primary PCI while 76 were administered with 300-mg. Patency of the IRA was significantly higher in patients administered with 600-mg loading clopidogrel therapy as compared with those who received 300-mg loading clopidogrel (94.8% vs. 85.5%, P = 0.038). 600-mg loading dose of clopidogrel was associated with lower incidence of 30-day MACEs compared with 300-mg loading dose of clopidogrel (8.3% vs. 19.7%, P = 0.029) while did not increase the risk of TIMI major (3.1% vs. 3.9%, P = 0.770) and minor bleeding (10.4% vs. 6.6%, P = 0.376). Conclusion 600-mg loading clopidogrel improves final patency of the IRA and clinical outcome as compared with 300-mg loading clopidogrel without increasing bleeding hazard.     

高敏C反应蛋白与不稳定心绞痛行介入术预后的关系

目的　探讨低密度脂蛋白(LDL-C)正常的不稳定心绞痛患者超敏C-反应蛋白(hs-CRP) 浓度对经皮穿刺冠脉介入治疗(PCI)术后预后的影响。方法　不稳定心绞痛患者在PCI术前测定血清hs-CRP浓度，术后随访9个月，期间观察主要不良心血管事件（MACE）的发生率。结果　hs-CRP浓度正常组主要不良心血管事件发生率显著低于hs-CRP浓度增高组(P < 0.05)。结论 hs-CRP浓度水平与PCI术后主要不良心血管事件的发生有相关性，可作为PCI术后主要不良心血管事件的预测指标。     

大骨节病病因研究新假说——产生硫酸软骨素CHS酶的厌氧菌是…

在益都、永寿ＫＢＤ患区水源中分出产ＣＨＳ酶厌氧菌，并能引致小鼠关节软骨损害的基础上，近一步在新病例较多的天水、汉源作病因调查，并以骺板软骨发育变化为指征研究ＫＤＢ成因。发现４患区水源均被粪便严重污染。     

26例胸腺瘤合并重症肌无力的外科治疗

胸腺瘤是前纵隔最常见的肿瘤,合并重症肌无力(myasthenia gravis MG)并不少见,治疗上较棘手.除肿瘤具有浸润性倾向外,MG自身免疫变化亦加重了治疗的复杂性.尤其是术后重症肌无力危象给手术增加难度.我院自1998年9月至2006年9月共收治胸腺瘤合并MG26例,均行手术治疗,取得较好疗效,现报告如下.